{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T02:53:26Z","timestamp":1767149606987,"version":"build-2238731810"},"update-to":[{"DOI":"10.1016\/j.vaccine.2023.08.054","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000}}],"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"am","delay-in-days":326,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["JP19fk0108113"],"award-info":[{"award-number":["JP19fk0108113"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["JP22fk0108637"],"award-info":[{"award-number":["JP22fk0108637"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["JP223fa627001"],"award-info":[{"award-number":["JP223fa627001"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["JP20fk0108104"],"award-info":[{"award-number":["JP20fk0108104"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.vaccine.2025.126880","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T22:43:02Z","timestamp":1740091382000},"page":"126880","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Correction to \u201cRecombinant Spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2\u201d [Vaccine 22 (41) (2023) 6025\u20136035]"],"prefix":"10.1016","volume":"52","author":[{"given":"Shiho","family":"Chiba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Halfmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Iida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tammy","family":"Armbrust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Spyra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Kawaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.126880_bb0005","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2025.126880_bb0010","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","article-title":"Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape","volume":"21","author":"Tregoning","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2025.126880_bb0015","article-title":"An overview of vaccine adjuvants: current evidence and future perspectives","volume":"10","author":"Facciola","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.126880_bb0020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2567.2009.03164.x","article-title":"T-helper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection","volume":"129","author":"Korsholm","year":"2010","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2025.126880_bb0025","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.0818-9641.2004.01286.x","article-title":"Aluminium compounds for use in vaccines","volume":"82","author":"Lindblad","year":"2004","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.vaccine.2025.126880_bb0030","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1080\/21645515.2016.1154247","article-title":"Comparative preclinical evaluation of AS01 versus other adjuvant systems in a candidate herpes zoster glycoprotein E subunit vaccine","volume":"12","author":"Fochesato","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.126880_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108216","article-title":"Immune response of C57BL\/6J mice to herpes zoster subunit vaccines formulated with nanoemulsion-based and liposome-based adjuvants","volume":"101","author":"He","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.vaccine.2025.126880_bb0040","doi-asserted-by":"crossref","first-page":"7892","DOI":"10.1016\/j.vaccine.2020.10.064","article-title":"NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge","volume":"38","author":"Guebre-Xabier","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126880_bb0045","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 Covid-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.126880_bb0050","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41467-020-20653-8","article-title":"SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice","volume":"12","author":"Tian","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.126880_bb0055","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/00063030-200822050-00001","article-title":"Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza a subtype H5N1 virus","volume":"22","author":"Carter","year":"2008","journal-title":"BioDrugs"},{"key":"10.1016\/j.vaccine.2025.126880_bb0060","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.vaccine.2025.126880_bb0065","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.abd0826","article-title":"Structure-based design of prefusion-stabilized SARS-CoV-2 spikes","volume":"369","author":"Hsieh","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2025.126880_bb0070","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41586-022-05482-7","article-title":"Characterization of SARS-CoV-2 omicron BA.4 and BA.5 isolates in rodents","volume":"612","author":"Uraki","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2025.126880_bb0075","doi-asserted-by":"crossref","first-page":"16587","DOI":"10.1073\/pnas.2009799117","article-title":"Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development","volume":"117","author":"Imai","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2025.126880_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.06.020","article-title":"Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum","volume":"184","author":"Liu","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2025.126880_bb0085","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1126\/science.abe8499","article-title":"SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo","volume":"370","author":"Hou","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2025.126880_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.06.043","article-title":"Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus","volume":"182","author":"Korber","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2025.126880_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.07.012","article-title":"The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity","volume":"182","author":"Li","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2025.126880_bb0100","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1182\/blood-2015-09-625343","article-title":"Influence of immunoglobulin isotype on therapeutic antibody function","volume":"127","author":"Beers","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2025.126880_bb0105","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41541-022-00472-2","article-title":"Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice","volume":"7","author":"Grigoryan","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2025.126880_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23094902","article-title":"Low-dose SARS-CoV-2 S-trimer with an emulsion adjuvant induced Th1-biased protective immunity","volume":"23","author":"Liao","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.vaccine.2025.126880_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1020159","article-title":"Immunological study of COVID-19 vaccine candidate based on recombinant spike trimer protein from different SARS-CoV-2 variants of concern","volume":"13","author":"Rudi","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.126880_bb0120","article-title":"S trimer derived from SARS-CoV-2 B.1.351 and B.1.618 induced effective immune response against multiple SARS-CoV-2 variants","volume":"11","author":"Wang","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.126880_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3001384","article-title":"Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus","volume":"19","author":"Amanat","year":"2021","journal-title":"PLoS Biol"},{"key":"10.1016\/j.vaccine.2025.126880_bb0130","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41392-022-00926-y","article-title":"Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.vaccine.2025.126880_bb0135","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2025.126880_bb0140","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41586-022-04460-3","article-title":"T cell responses to SARS-CoV-2 spike cross-recognize omicron","volume":"603","author":"Keeton","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2025.126880_bb0145","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-022-04465-y","article-title":"Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 omicron","volume":"603","author":"Liu","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2025.126880_bb0150","article-title":"Divergent SARS-CoV-2 omicron-reactive T and B cell responses in COVID-19 vaccine recipients","volume":"7, eabo2202","author":"GeurtsvanKessel","year":"2022","journal-title":"Sci Immunol"},{"key":"10.1016\/j.vaccine.2025.126880_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2022.01.015","article-title":"SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from alpha to omicron","volume":"185","author":"Tarke","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2025.126880_bb0160","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/imr.13089","article-title":"Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines","volume":"310","author":"Sette","year":"2022","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2025.126880_bb0165","first-page":"1","article-title":"Saponins as vaccine adjuvants","volume":"13","author":"Kensil","year":"1996","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"10.1016\/j.vaccine.2025.126880_bb0170","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1631\/jzus.2007.B0153","article-title":"Adjuvant effects of saponins on animal immune responses","volume":"8","author":"Rajput","year":"2007","journal-title":"J Zhejiang Univ Sci B"},{"key":"10.1016\/j.vaccine.2025.126880_bb0175","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cyto.2015.05.010","article-title":"T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production","volume":"75","author":"Zhu","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.vaccine.2025.126880_bb0180","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.vaccine.2011.01.011","article-title":"Adjuvant system AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity","volume":"29","author":"Morel","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126880_bb0185","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.vaccine.2016.02.012","article-title":"Comparison of AS03 and alum on immune responses elicited by A\/H3N2 split influenza vaccine in young, mature and aged BALB\/c mice","volume":"34","author":"Yam","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126880_bb0190","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3389\/fimmu.2015.00207","article-title":"AS03-Adjuvanted, very-low-dose influenza vaccines induce distinctive immune responses compared to Unadjuvanted high-dose vaccines in BALB\/c mice","volume":"6","author":"Yam","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.126880_bb0195","doi-asserted-by":"crossref","first-page":"6166","DOI":"10.4049\/jimmunol.164.12.6166","article-title":"M-1\/M-2 macrophages and the Th1\/Th2 paradigm","volume":"164","author":"Mills","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2025.126880_bb0200","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12866-018-1186-8","article-title":"Comparative analysis of humoral immune responses and pathologies of BALB\/c and C57BL\/6 wildtype mice experimentally infected with a highly virulent Rodentibacter pneumotropicus (Pasteurella pneumotropica) strain","volume":"18","author":"Fornefett","year":"2018","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.vaccine.2025.126880_bb0205","doi-asserted-by":"crossref","first-page":"21849","DOI":"10.1038\/s41598-021-01363-7","article-title":"Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant","volume":"11","author":"Akache","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2025.126880_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2025.126880_bb0215","article-title":"An established Th2-oriented response to an alum-Adjuvanted SARS-CoV-2 subunit vaccine is not reversible by sequential immunization with nucleic acid-Adjuvanted Th1-oriented subunit vaccines","volume":"9","author":"Cao","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.126880_bb0220","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202104362","article-title":"Hydrogel-based slow release of a receptor-binding domain subunit vaccine elicits neutralizing antibody responses against SARS-CoV-2","volume":"33","author":"Gale","year":"2021","journal-title":"Adv Mater"},{"key":"10.1016\/j.vaccine.2025.126880_bb0225","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.729189","article-title":"A combination adjuvant for the induction of potent antiviral immune responses for a recombinant SARS-CoV-2 protein vaccine","volume":"12","author":"Jangra","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.126880_bb0230","article-title":"An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor-binding domain vaccine in aged mice","volume":"eabj5305","author":"Nanishi","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2025.126880_bb0235","doi-asserted-by":"crossref","first-page":"8761","DOI":"10.1038\/s41598-021-88283-8","article-title":"CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge","volume":"11","author":"Lien","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2025.126880_bb0240","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abh3634","article-title":"A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates","volume":"6","author":"Pino","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.vaccine.2025.126880_bb0245","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1038\/s41467-021-23942-y","article-title":"SARS-CoV-2 RBD trimer protein adjuvanted with alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung","volume":"12","author":"Routhu","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.126880_bb0250","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg1143","article-title":"A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters","volume":"13","author":"Wu","year":"2021","journal-title":"Sci Transl Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2500177X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2500177X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T17:40:39Z","timestamp":1762278039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2500177X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":50,"alternative-id":["S0264410X2500177X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126880","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correction to \u201cRecombinant Spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2\u201d [Vaccine 22 (41) (2023) 6025\u20136035]","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126880","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.08.054","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126880"}}